Integra Lifesciences Holdings (IART) Price to Earnings (2009 - 2026)

Integra Lifesciences Holdings has disclosed Price to Earnings across 18 years of filings, most recently posting 311.65 for Q2 2026.

• In Q2 2026, Price to Earnings rose 15880.81% year-over-year to 311.65; the TTM figure through Jun 2026 stood at 192.85 (down 9999.16% YoY), while the FY2025 annual figure was 1.87, up 99.26% from the prior year.
• Price to Earnings came in at 311.65 for Q2 2026 at Integra Lifesciences Holdings, up from 158.73 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 800.22 in Q2 2023 to a low of 851.4 in Q1 2024.
• Average Price to Earnings over 5 years is 1.46, with a median of 78.66 recorded in 2022.
• Year-over-year, Price to Earnings plunged 730.4% in 2025 and surged 15880.81% in 2026.
• Over 5 years, Price to Earnings stood at 86.45 in 2022, then jumped by 98.66% to 171.75 in 2023, then tumbled by 47.53% to 90.11 in 2024, then sank by 730.4% to 568.06 in 2025, then jumped by 154.86% to 311.65 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 311.65 in Q2 2026, 158.73 in Q1 2026, and 568.06 in Q4 2025.